Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT01852968 |
| Other study ID # |
1301M26901 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
May 2013 |
| Est. completion date |
October 31, 2017 |
Study information
| Verified date |
December 2021 |
| Source |
University of Minnesota |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
The hippocampus is an area of brain which plays an essential role in learning and memory
processing and is thought to be particularly vulnerable to effects of hypoglycemia (low blood
glucose). The goal of this project is to examine hippocampal neurochemistry and metabolism
and identify how diabetes and recurrent hypoglycemia alter the hippocampus.
Description:
In this study we will examine hippocampal neurochemical profile and glucose transport
kinetics using magnetic resonance spectroscopy (MRS) in patients with type 1 diabetes and
hypoglycemia unawareness and matched healthy controls. We will also examine hippocampal
function in these subject groups during euglycemia and hypoglycemia and correlate these
findings to changes in the neurochemical profile and glucose transport kinetics.
Study protocol
MRS experiments On the morning of the MRS experiments, subjects will present to the Center
for Magnetic Resonance Research (CMRR) at 7 AM in the fasting state to participate in a
protocol with which our group has significant experience. After arrival, they will be
prepared for the clamp study by the placement of one intravenous catheter into one vein in
antecubital fossa for the later infusion of glucose, insulin, and potassium. A second
intravenous catheter will be placed retrograde into a vein in the distal leg for later blood
sampling. An intravenous infusion of insulin will then be started and adjusted as necessary
to bring blood glucose to 95 mg/dl. Blood will be collected every 10 minutes for measurement
of glucose on a nearby Analox machine to guide adjustments in the insulin infusion rate. The
experiment will begin when the subject is at 95 mg/dl. At time 0, the intravenous insulin
infusion will be fixed at 1 mU/kg/min, samples for blood glucose will be collected every 5
minutes and an intravenous infusion of glucose (20% dextrose) will be administered as
necessary to maintain blood glucose at 95 mg/dl. At +5 minutes, subjects will be placed into
the magnet. Blood glucose will be maintained at 95 mg/dl during the next 25 minutes as the
hippocampal volume-of-interest (VOI) is selected and baseline MRS data are acquired. At + 30
min, subjects will be given an intravenous bolus injection of glucose over 1-2 minutes using
the formula of administering 2 mg glucose/kg body weight for each 1 mg/dl increase desired
that our group have used with success previously. Immediately after the bolus injection, a
continuous infusion of 20% dextrose will be started and the rate of administration will be
adjusted to maintain the desired glucose target of 200 mg/dl, 300 mg/dl, or 400 mg/dl. MRS
data will be collected continuously starting 10 minutes before the bolus injection (baseline)
until the end of the study ~60 minutes after the bolus, which is sufficient to reach
steady-state glucose concentrations in the brain and maintain them for at least 20 minutes.
At the completion of the study, the infusions will be discontinued; the subject will resume
their usual insulin regimen, and be fed a meal. The subjects with diabetes will be prepared
for this protocol by instructing them to manage their diabetes in such a way as to minimize
the amount of subcutaneous insulin present at the time of the study without creating
hyperglycemia on the day before the study (i.e. pump patients will stop their pump on
arrival, glargine treated patients will take last glargine dose 24 hours before study start).
At the conclusion of the study, subjects will be allowed to resume their usual insulin
regimen.
Neurocognitive testing On the morning of the Neurocognitive testing, subjects will present to
the Clinical and Translational Science Institute at 7 AM in the fasting state. Subjects with
diabetes will have their blood glucose checked to ensure that blood glucose is between 90-200
mg/dl. If the blood glucose is not in target range, treatment will be given to correct
glucose or the study will be rescheduled. Subjects will undergo neurocognitive testing with
the California Verbal Learning Test - Second Edition (CVLT-II) and subtests from the
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Story Memory
(immediate and delayed), Digit Span, and Coding. After completion of neurocognitive testing,
an intravenous catheter will be placed antegrade in each forearm for subsequent infusions and
for blood sampling. Insulin will be infused at a rate of 2.0 mU/kg/min along with potassium
phosphate (4 mEq/hour) and blood glucose will reduced to and then maintained at 55 mg/dl by
the variable infusion of 20% dextrose. Samples for blood glucose will be collected every 5
minutes for measurement of glucose. Once the blood glucose target of 55 is achieved subject
will undergo neurocognitive testing again. At the completion of the neurocognitive testing
subjects will be fed and euglycemia will be restored.
